• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Dermatologic screening demands may exceed recommended follow-up frequencies

byAngela WangandAdam Whittington
July 20, 2014
in Dermatology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with pigmented skin lesions demanded more screening visits than the recommended amount in pigmented lesion clinics (PLCs). 

2. The highest percentages of follow-up requests were associated with patients who had diagnoses of Spitz nevi and atypical nevus syndrome. 

Evidence Rating Level: 2 (Good) 

Study Rundown: Diagnoses of skin cancers such as melanoma often warrant a recommended number of follow-up visits for total body skin examinations (e.g. every 3 months for the first 2 years, every 6 months for the next 2 years, and annually afterwards).  However, patients may request additional screening visits in PLCs, contributing to increased patient volume.  This study sought to quantify these additional screening visits and determine patient characteristics associated with more frequent visits.  Results indicated that 14.9% of visits in PLCs were categorized as additional screening visits and 30% of patients had more frequent screening than the recommended amount.  Additional visits were associated with patients who had a previous diagnosis of Spitz nevus, atypical nevus syndrome, atypical nevus, and invasive melanoma. Strengths of this study included its discussion on possible solutions for increased patient loads in PLCs.  However, as a single-center study, generalization of results may be limited.

Click to read the study in JAMA Dermatology

Relevant Reading: Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma

In-Depth [retrospective cohort]: This study analyzed 584 patients and 1730 visits at the Dermatology PLC at Emory University between October 2010 and January 2012.  Patients with history of MIS, invasive melanoma, dysplastic nevi, atypical nevus syndrome, and Spitz nevi were included in the study, and their electronic medical charts were reviewed for additional visits in excess of recommended follow-ups.  Patient characteristics such as family history of melanoma, other risk factors, and demographic information were also collected.  Results were analyzed using χ2 tests.  Of the 1730 visits, 1400 (80.9%) were standard follow-up visits, 257 (14.9%) were additional screening visits, and 73 (4.2%) were classified as “problem-focused” visits.  Additional visits were less associated with patients who had “family history only” and “other risk factors” compared to patients who had personal history of dysplastic nevus, melanoma, atypical nevus syndrome, or Spitz nevus (P=0.04)

RELATED REPORTS

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma

More from this author: Video-based behavioral intervention benefits clinical skin examinations, Biofilm-producing staphylococci occlude eccrine sweat ducts in atopic dermatitis, Initial primary invasive or in situ melanoma increases risk of subsequent invasive melanoma, Various factors impact quality of life in patients with chronic pruritus, New Mohs sterilization guidelines may not affect infection rates 

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: skin cancer
Previous Post

Functional decline in children with retinoblastoma greater than expected

Next Post

American-born Asian women more likely to have endometrial cancer

RelatedReports

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
StudyGraphics

#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma

March 15, 2023
#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
StudyGraphics

#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma

March 9, 2023
#VisualAbstract: Adjuvant pembrolizumab improves distant  metastasis-free survival in stage IIB-C melanoma
StudyGraphics

#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma

February 13, 2023
#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer
StudyGraphics

#VisualAbstract: Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma

October 20, 2022
Next Post
American-born Asian women more likely to have endometrial cancer

American-born Asian women more likely to have endometrial cancer

Severe maternal childhood abuse associated with autism in offspring

Peer-mentored therapy reduces distress in mothers of children with disabilities

3D mammography (tomosynthesis) enhances accuracy of breast cancer screening

Minimal survival benefit from contralateral prophylactic mastectomy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Synergistic interaction between risk burden and genetics for atrial fibrillation development
  • Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma
  • Specific histopathologic renal lesions may be associated with increased risk of cardiovascular disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options